ACADIA PHARMACEUTICALS INC

Acadia’s DAYBU receives a positive EMA review, paving the way for the first EU treatment of Rett syndrome and sparking a 10% share rally.

ACADIA Pharmaceuticals’ stock swings 58% in a year, spotlighting risks of its CNS drug pipeline and investor uncertainty.

Explore Acadia Pharmaceuticals: a San Diego‑based biotech driving small‑molecule CNS therapies, its $4.25B market cap, recent $25.13 share price, and growth outlook.

Acadia Pharmaceuticals’ stock surged 26% after a US court ruled in its favor on a patent case, securing protection for its flagship Parkinson’s disease treatment, NUPLAZID, until 2038.

ACADIA Pharmaceuticals Inc. has experienced significant growth and success, including a recent legal victory that secures patent protection for its NUPLAZID formulation until 2038, positioning the company for future growth in the biotechnology sector.

ACADIA Pharmaceuticals Inc. has seen fluctuations in its stock performance over the past year, with a market capitalization of $2.44 billion and a price-to-earnings ratio of 10.73, reflecting its significant presence in the biotechnology sector.

Acadia Pharmaceuticals Inc. reported positive Q1 earnings, driving its stock price up and solidifying its position as a leader in the biopharmaceutical industry.

ACADIA Pharmaceuticals Inc. has demonstrated resilience and growth amidst market fluctuations, exceeding earnings expectations and positioning itself for sustained growth in the biopharmaceutical industry.

ACADIA Pharmaceuticals Inc. exceeded earnings and revenue estimates in Q1 2025, showcasing its resilience and growth potential in the competitive biotechnology sector.